Cart 0 Product Products (empty)
No products
To be determined Shipping
0,00 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products (tax excl.)
Total shipping (tax excl.) To be determined
Total (tax excl.)
Data sheet of Mouse Monoclonal to CD255 / TWEAK
| Brand | Exbio |
| Product type | Primary antibodies |
| Reactivity | Human |
| Clonality | Monoclonal |
More info about Mouse Monoclonal to CD255 / TWEAK
| Brand: | Exbio |
| Product no.: | 11-756-C025 |
| Product type: | Primary antibodies |
| Host species: | Mouse |
| Product name: | Mouse Monoclonal to CD255 / TWEAK |
| Antigen: | CD255 / TWEAK |
| Clonality: | Monoclonal |
| Clone: | CARL-1 |
| Isotype: | IgG3 |
| Immunogen: | human CD255-transfected 2PK-3 cells |
| Format: | purified |
| Specificity: | The mouse monoclonal antibody CARL-1 recognizes CD255 / TWEAK, a type II transmembrane protein of the TNF superfamily able to weakly induce apoptosis in many cell types. |
| Categories: | Apoptosis (Human), CD and Related Antigens (Human) |
| Concentration: | 1 mg/ml |
| Storage buffer: | Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4 |
| Storage / stability: | Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label. |
| Background: | CD255 / TWEAK (TNF-related weak inducer of apoptosis), a type II transmembrane protein expressed as membrane-bound and secreted form, can induce apoptosis in many tissues and cell lines through its receptor CD266 / TWEAK R. On the other hand, in endothelial cells this interaction can induce proliferation and promote angiogenesis including neovascularization of tumours. CD255 can act in a juxtacrine manner to initiate cellular responses, and induces secretion of pro-inflammatory cytokines. Besides CD266, CD255 may also bind to DR3. |
| Purity: | > 95% (by SDS-PAGE) |
| Purification: | Purified by protein-A affinity chromatography |
| Product specific references: | *Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med. 2011 Jan;2(1):103-108, *Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol. 2003 Jan 1;170(1):341-8., *Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T: Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol. 2006 Dec;146(3):540-9., *Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S: TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem. 2003 Sep 19;278(38):36005-12., *Brown SA, Ghosh A, Winkles JA: Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem. 2010 Jun 4;285(23):17432-41._x000D_ , *Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H: Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med. 2000 Nov 6;192(9):1373-80. |
| Related products: | - Mouse Monoclonal to CD262 / TRAIL-R2 - Mouse Monoclonal to CD26 - Mouse Monoclonal to CD261 / TRAIL-R1 / DR4 |
| Shipping condition: | Room temperature |